• 1. Highly stereocontrolled total synthesis of (+)-bengamide E
  Chisato Mukai,Sameh M. Moharram,Osamu Kataoka,Miyoji Hanaoka J. Chem. Soc. Perkin Trans. 1 1995 2849

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azepines Azepines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azepines
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Recent Advances in the Study of 3-Aminoazepan-2-one (CAS: 671-42-1): A Comprehensive Research Brief

3-Aminoazepan-2-one (CAS: 671-42-1) has recently emerged as a compound of significant interest in the field of chemical biology and medicinal chemistry. This seven-membered lactam, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its synthetic pathways, biological activities, and potential as a scaffold for drug development. The compound's ability to mimic natural peptide structures while offering enhanced metabolic stability makes it particularly attractive for pharmaceutical research.

A 2023 study published in the Journal of Medicinal Chemistry explored novel synthetic routes for 3-Aminoazepan-2-one, demonstrating improved yields and purity compared to traditional methods. The research team developed a catalytic asymmetric synthesis approach that achieved enantiomeric excess values exceeding 95%, addressing previous challenges in stereochemical control. This advancement is particularly significant as the stereochemistry of 3-Aminoazepan-2-one derivatives has been shown to critically influence their biological activity and pharmacokinetic properties.

In the realm of biological applications, recent investigations have revealed that 3-Aminoazepan-2-one derivatives exhibit potent inhibitory effects against several clinically relevant enzymes. A 2024 study in ACS Chemical Biology reported the development of a series of 3-Aminoazepan-2-one-based inhibitors targeting proteases involved in viral replication, with some compounds demonstrating nanomolar potency against SARS-CoV-2 main protease. The structural flexibility of the 3-Aminoazepan-2-one scaffold allowed for fine-tuning of selectivity and potency, highlighting its versatility in drug design.

Pharmacokinetic studies published in Drug Metabolism and Disposition (2023) have provided new insights into the metabolic stability and bioavailability of 3-Aminoazepan-2-one derivatives. The research demonstrated that certain N-substituted derivatives exhibited significantly improved oral bioavailability compared to the parent compound, with favorable tissue distribution profiles. These findings suggest that 3-Aminoazepan-2-one could serve as an excellent starting point for developing orally active therapeutic agents.

Recent computational studies have further expanded our understanding of 3-Aminoazepan-2-one's molecular interactions. Molecular docking and dynamics simulations published in the Journal of Chemical Information and Modeling (2024) revealed that the compound's seven-membered ring structure allows for unique binding conformations not accessible to smaller ring systems. This property may explain the observed selectivity of certain derivatives for specific biological targets, opening new avenues for structure-based drug design.

The safety profile of 3-Aminoazepan-2-one derivatives has also been the subject of recent investigation. A comprehensive toxicological assessment published in Regulatory Toxicology and Pharmacology (2023) evaluated a series of derivatives, finding that most compounds exhibited favorable safety margins in preclinical models. Importantly, the study identified structural modifications that could further enhance the therapeutic index of these compounds, providing valuable guidance for future medicinal chemistry optimization.

Looking forward, the unique properties of 3-Aminoazepan-2-one position it as a promising scaffold for addressing several unmet medical needs. Current research efforts are exploring its application in neurological disorders, with preliminary data suggesting potential as a modulator of neurotransmitter systems. Additionally, its utility in antibiotic development is being investigated, particularly against drug-resistant bacterial strains. As synthetic methodologies continue to advance and our understanding of its biological interactions deepens, 3-Aminoazepan-2-one is poised to play an increasingly important role in pharmaceutical development.

• 21568-87-6((3S)-3-aminoazepan-2-one)
• 17929-90-7(3-Amino-2-azepanone)
• 88763-76-2((R)-3-Aminopiperidine-2-one)
• 1892-22-4(3-Aminopiperidin-2-one)
• 34294-79-6((s)-3-Aminopiperidin-2-one)
• 29426-64-0(3-Aminoazepan-2-one hydrochloride)
• 28957-33-7((3R)-3-aminoazepan-2-one)
• 60654-08-2(Hexanamide, 2,6-diamino-N-dodecyl-, (S)-)
• 26081-03-8((R)-3-Aminoazepan-2-One Hydrochloride)
• 60209-20-3(Lycetamine)